坎地沙坦治疗急性心肌梗死后心肌重塑的疗效观察被引量：2

Effect Observation of Candesartan on myocardial remodeling after acute myocardial infarction

导出

摘要目的观察坎地沙坦对急性心肌梗死后心肌重塑-心室重塑的影响。方法选择2013年3月—2014年2月郑州大学第二附属医院住院的急性心肌梗死患者306例,随机分为缬沙坦治疗组和坎地沙治疗坦组,疗程20周。观察两组治疗前后左室舒张末期内径、左室射血分数、基质金属蛋白酶-9(MMP-9)、高敏C-反应蛋白(hs-CRP)及肿瘤坏死因子-α(TNF-α)水平变化。结果治疗前后左室舒张末期内径、MMP-9、水平明显降低(P<0.05);左室射血分数明显提高(P<0.05)。结论坎地沙坦可以改善急性心肌梗死后的心肌重塑,并减少器官中MMP-9、hs-CRP、TNF-α水平。 Objective To observe the effects of candesartan on myocardial remodeling after acute myocardial infarction. Methods Totally 306 cases of acute myocardial infarction patients selected from June 2010 to June 2013 in our hospital were randomly divided into valsartan treatment group and candesartan treatment group, treatment for 20 weeks, changes in left ventricular end diastolic diameter, left ventricular ejection fraction and blood MMP - 9, hs - CRP, TNF -α levels of the two groups were observed before and after treatment. Results Before and after the treatment, the left ventricular end diastolic diameter, blood MMP - 9, hs - CRP, TNF - α evels were significantly decreased （ P 〈 0. 05 ） , and left ventricular ejection fraction was significantly increased （P 〈 0. 05）. Conclusion Candesartan can reduce the myocardial remodeling after acute myocardial infarction, and can reduce the MMP - 9, hs - CRP, TNF -α expression levels.

作者师振霞邵磊

机构地区河南工程学院校医院郑州大学第二附属医院

出处《医药论坛杂志》 2015年第5期15-16,19,共3页 Journal of Medical Forum

基金河南省科技厅基础与前沿技术研究计划项目(132300410418)

关键词心肌梗死坎地沙坦左室舒张末期内径左室射血分数 Myocardial infarction Candesartan Left ventricular end diastolic diameter Left ventricular ejection fraction

分类号 R542.2 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献6

1《慢性心力衰竭规范化治疗推广项目》2011.
2P1 ehn JF, Davi S BR,SaCk FM, et al. Reduction Of St roke inci- dence after myocardial infarction with rava statin:the Cholesterol and Recurtent o E vent S ( CARE StudY. The Care I nve stigat 0 r s[J]. Ci rculatiOn,1999,99(2) :216-223.
3Wong B,Lumma WC,Smith AM,et 81. Statins siippress THP -1 cell nligratin and secretion of mat rimetalloproteina Se 9 by in- hibiting geranylgeranylation [ J ]. J Leukoc Biol, 2001,69 ( 6 ) : 959-962.
4Verdechia P, Poreellati C, Reboldic, et al. Leftventricu21ar hy- pertrophy as an independent predictor of acute cerebrovascu2 lar events in essential hypertension [ J]. Circulation, 2001, 104 (17) : 2 039-2 044.
5Ferrario CM, Strawn WB. Role of the rennin - angiotensin - aldo- sterone system and proinflammatory mediators in cardiovascular disease[ J]. Am J Cardio1.2006.98 ( 1 ) : 121-128.
6刘丽梅,朱绍亨,罗瑞英.肾素-血管紧张素系统与心房重构关系的研究进展[J].福建医药杂志,2009,31(1):90-92. 被引量：3

二级参考文献14

1Goette A, Staack T, Roeken C, et al. Increased expression of extraeellular signal-regulated kinase and angiotensin-eonverting enzyme in human atria during atrial fibrillation[J]. J Am Coll Cardiol. 2000, 35 (6): 1669-1677.
2Madrid AH, Bueno MG, Rebolo JM, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospeetive and randomized study [J]. Circulation. 2002, 106(3): 331-336.
3Le-Heuzey JY, Marijon E, Chachoua K, et al. Pathophysiology of atrial fibrillation: Insights into the renin-angiotensin system [J]. Arch Cardiovasc Dis, 2008, 101 (11-12): 189-791.
4Brundel BJ, Henning RH, Kampinga HH, et al. Molecular mechanisms of remodeling in human atrial fibrillation [J]. Cardiovascular Research, 2002, 54 (2): 315.
5Ausma J, van-der-Velden HM, Lenders MH. et al. Reverse structural and gap-junctional remodeling after prolonged atrial, fibrillation in the goat [J]. Circulation, 2003, 107 (15): 2051.
6Gassanov N, Brandt MC, Michels G, et al. Angiotensin Ⅱ-induced changes of calcium sparks and ionic currents in human atrial myocytes : Potent ial role for earlyr emodeling in atri al fibrillation [J]. Cell Calcium, 2006, 39 (2): 175-186.
7Cha TJ, Ehrilich JR, Zhang L, et al. Dissociation between ionic remodeling and ability to sustain atrial fibrillation during recovery from experimental congestive heart failure [ J ]. Circulation, 2004, 109 (3): 412-418.
8Vn-Lewinski D, Kockskamper J, Rubertus SU, et al. Directpro-arrhythmogenic effects of angiotensin Ⅱ can be suppressed by AT (1) receptor blockade in human atrial myocardium [J]. Eur J Heart Fail, 2008, 10 (12) : 1172-1176.
9Nakashima H, KumagaiK, Urata H, etal. Angiotensin Ⅱ antagonist prevents electrical remodelling in atrial fibrillatin [J]. Circulation, 2000, 101 (22): 2612-2617.
10Li D, Shinagawa K, Pang I, et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substratein dogs with ventricular taehypaeing-induced con gestire heart failure [J]. Circulation, 2001, 104 (21):2608-2614.